Magali Waelbroeck

Overview

Best Publications

• Ghrelin Degradation by Serum and Tissue Homogenates: Identification of the Cleavage Sites

  Carine De Vriese;Francoise Gregoire;Roger Lema-Kisoka;Magali Waelbroeck

  357
  Citations

• Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain

  Magali Waelbroeck;Michèle Tastenoy;Jean Claude Camus;Jean Christophe

  348
  Citations

• Development of high affinity selective VIP1 receptor agonists

  Philippe Gourlet;Andre Vandermeers;Pascale Vertongen;Jean Rathe

  271
  Citations

• In vitro properties of a high affinity selective antagonist of the VIP1 receptor

  Philippe Gourlet;Philippe de Neef;Johnny Cnudde;Magali Waelbroeck

  250
  Citations

• Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.

  M. Svoboda;M. Tastenoy;J. Vanrampelbergh;J.F. Goossens

  235
  Citations

• Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

  Magali Waelbroeck;Patrick Robberecht;David H. Coy;Jean-Claude Camus

  218
  Citations

• The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass

  Philippe Gourlet;Pascale Vertongen;Andre Vandermeers;Marie-Claire Vandermeers-piret

  213
  Citations

• Techniques: Promiscuous Gα proteins in basic research and drug discovery

  Evi Kostenis;Magali Waelbroeck;Graeme Milligan

  190
  Citations

• Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes

  Günter Lambrecht;Roland Feifel;Monika Wagner-Röder;Carsten Strohmann

  138
  Citations

• Presence of vasoactive intestinal peptide receptors coupled to adenylate cyclase in rat lung membranes

  Patrick Robberecht;Pierre Chatelain;Philippe De Neef;Jean Claude Camus

  123
  Citations

• Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites.

  Magali Waelbroeck;Patrick Robberecht;Pierre Chatelain;Jean Christophe

  120
  Citations

• Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor

  D. Moreno;P. Gourlet;P. De Neef;J. Cnudde

  113
  Citations

• The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors

  Philippe Gourlet;Jean-Pierre Vilardaga;Philippe De Neef;Magali Waelbroeck

  110
  Citations

• Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.

  Patrick Robberecht;David H. Coy;Magali Waelbroeck;Mark L. Heiman

  110
  Citations

• Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination.

  J.P. Vilardaga;P. Deneef;E. Dipaolo;A. Bollen

  106
  Citations

• Heart receptors for VIP, PHI and secretin are able to activate adenylate cyclase and to mediate inotropic and chronotropic effects. Species variations and physiopathology

  Jean Christophe;Magali Waelbroeck;Pierre Chatelain;Patrick Robberecht

  105
  Citations

• Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom.

  André Vandermeers;Marie Claire Vandermeers-Piret;Patrick Robberecht;Magali Waelbroeck

  101
  Citations

• Kinetic studies of [3H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: evidence for the existence of three classes of binding sites.

  Magali Waelbroeck;Michel Gillard;Patrick Robberecht;Jean Christophe

  98
  Citations

• The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.

  Jean Van Rampelbergh;Piotr Poloczek;Isabelle Françoys;Christine Delporte

  98
  Citations

• The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors.

  P Robberecht;M Delhaye;G Taton;P De Neef

  92
  Citations